Grufity logo
Grufity logo
LRMR

LRMR - Larimar Therapeutics, Inc. Stock Price, Fair Value and News

$3.80-0.12 (-3.06%)
Market Closed as of 14 Sep 2026, 04:00 pm ET

Price Targets

LRMR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LRMR Price Action

Last 7 days

-0.8%

Last 30 days

-12.8%

Last 90 days

11.8%

Trailing 12 Months

-3.3%

LRMR RSI Chart

LRMR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LRMR Valuation

Market Cap

394.8M

Price/Earnings (Trailing)

-2.29

Price/Sales (Trailing)

188.13

EV/EBITDA

-2.12

Price/Free Cashflow

-3.76

LRMR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

LRMR Fundamentals

LRMR Revenue

Revenue (TTM)

2.3M

LRMR Earnings

Earnings (TTM)

-172.6M

Earnings Growth (Yr)

-25.21%

Earnings Growth (Qtr)

-10.7%

LRMR Profitability

EBT Margin

-7317.71%

Return on Equity

-135.5%

Return on Assets

-104.42%

Free Cashflow Yield

-26.6%

LRMR Investor Care

Shares Dilution (1Y)

62.25%

Revenue & Growth

How Larimar Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20192.3M---
20181.0M1.1M1.5M1.9M
2017912.0K934.0K970.0K996.0K
2016608.0K770.0K857.0K894.0K
2015130.5K233.0K335.5K438.0K
2014---28.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Larimar Therapeutics, Inc.

LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
 CEO
 WEBSITElarimartx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

Larimar Therapeutics, Inc. Frequently Asked Questions

LRMR is the stock ticker symbol of Larimar Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Larimar Therapeutics, Inc. is 394.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, LRMR's PE ratio (Price to Earnings) is -2.29 and Price to Sales (PS) ratio is 188.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LRMR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Larimar Therapeutics, Inc. has provided 0.019 (multiply by 100 for percentage) rate of return.